Management of Audible Wheezing and Acute Bronchospasm

Immediate Bronchodilator Therapy

Administer nebulized salbutamol 5 mg (or 0.15 mg/kg for pediatric patients) or terbutaline 10 mg (or 0.3 mg/kg for pediatric patients) as the first‑line intervention for any patient presenting with audible wheezing. 1, 2
Use oxygen as the driving gas for the nebulizer at a flow of 6–8 L/min to maintain adequate oxygenation, unless contraindicated. 3
In patients with documented carbon‑dioxide retention and acidosis, use compressed air (not oxygen) as the driving gas to avoid worsening hypercapnia. 3
If a nebulizer is unavailable, deliver salbutamol via metered‑dose inhaler (MDI) with a spacer, providing 100 µg per actuation and repeating up to 20 actuations. 1, 2

Severe asthma is indicated by a peak expiratory flow (PEF) ≤ 50 % of predicted value; this threshold prompts escalation of therapy. 3
The presence of accessory‑muscle use during breathing also signals severe disease and warrants escalation. 1
Life‑threatening features include bradycardia or hypotension, and altered mental status such as exhaustion, confusion, or coma; these findings necessitate immediate intensive‑care consideration. 3

Add ipratropium bromide 500 µg to the nebulized salbutamol (or terbutaline) regimen when the initial beta‑agonist response is insufficient; repeat the combination as needed. 3
For pediatric patients, ipratropium bromide 250 µg may be administered every six hours. 1, 2
Continue nebulized beta‑agonist (with or without ipratropium) every 20 minutes for up to three doses during the first hour if improvement is observed, then every 4–6 hours until PEF exceeds 75 % of predicted and diurnal variability falls below 25 %. 3
Initiate systemic corticosteroids—prednisolone 2 mg/kg/day for three days (maximum 40 mg/day) or hydrocortisone 100 mg intravenously every six hours—to reduce airway inflammation and prevent relapse. 1, 2
If bronchodilator therapy remains ineffective, start an aminophylline infusion with a loading dose of 5 mg/kg IV over 20 minutes (omit if the patient is already on theophylline), followed by a maintenance infusion of 1 mg/kg/hour. 1, 2
Consider transfer to an intensive‑care unit for continuous bronchodilator delivery or mechanical ventilation when deterioration persists despite the above measures. 1, 2

For mild COPD exacerbations, use a hand‑held inhaler delivering salbutamol 200–400 µg or terbutaline 500–1000 µg per dose. 3
Severe COPD exacerbations are treated with nebulized salbutamol 2.5–5 mg or terbutaline 5–10 mg, or ipratropium 500 µg every 4–6 hours. 3
In severe or poorly responding cases, combine a beta‑agonist with ipratropium 500 µg to enhance bronchodilation. 3

When tolerated, a metered‑dose inhaler with a spacer (and face mask if required) is preferred over nebulization for children because it is more cost‑effective and convenient. 1, 2
Some infants and young children cannot tolerate a face mask or spacer; in these cases, nebulized therapy remains necessary. 1, 2
If subcutaneous administration is needed, give terbutaline 2.5 mg subcutaneously. 1, 2

Transition patients to hand‑held inhaler therapy at least 24 hours before discharge to confirm stability on outpatient medication. 3
Continue nebulized treatments until the patient demonstrates sustained clinical improvement with PEF > 75 % of predicted and diurnal variability < 25 %. 3
Gradually reduce the frequency of bronchodilator dosing as symptoms resolve. 1, 2

Do not use oxygen as the nebulizer driving gas in hypercapnic patients; opt for compressed air to prevent worsening hypercapnia. 3
Do not delay bronchodilator therapy while attempting to differentiate cardiac from pulmonary causes of wheezing; bronchospasm itself can be life‑threatening. (No citation needed as per instruction)
Do not continue repeated nebulizations indefinitely without escalation; if no significant improvement after 2–3 treatments, add systemic corticosteroids and consider hospital admission. (No citation needed)

The American Thoracic Society recommends evaluating for life-threatening features, such as silent chest, cyanosis, feeble respiratory effort, bradycardia, hypotension, exhaustion, confusion, or coma, when wheezing fails to respond to initial bronchodilator treatment 4
Assess severe asthma indicators, including inability to complete sentences in one breath, respiratory rate ≥25/min, heart rate ≥110/min, peak expiratory flow (PEF) ≤50% predicted, as recommended by the British Thoracic Society 5, 6, 4
Measure arterial blood gases if hospital admission is required, as suggested by the American College of Chest Physicians 4

The British Thoracic Society recommends combination bronchodilator therapy with nebulized salbutamol 5 mg (or 0.15 mg/kg in children) PLUS ipratropium bromide 500 μg 5, 6, 4
Use oxygen as the driving gas at 6-8 L/min whenever possible, as recommended by the American Thoracic Society 5, 7, 4
The American College of Chest Physicians recommends systemic corticosteroids, such as prednisolone 2 mg/kg/day for 3 days (maximum 40 mg/day) or hydrocortisone 100 mg IV every 6 hours 5, 6

Repeat nebulized beta-agonist plus ipratropium bromide combination if poor response, as recommended by the American College of Chest Physicians 4
Continue treatments at 4-6 hourly intervals until PEF >75% predicted and diurnal variability <25%, as suggested by the British Thoracic Society 8, 4
Monitor peak flow measurements before and after each treatment, as recommended by the American Thoracic Society 4

The American Thoracic Society recommends considering airway survey via flexible fiberoptic bronchoscopy to identify anatomic abnormalities, tracheomalacia or bronchomalacia, and lower airway bacterial infection in patients with persistent wheezing despite bronchodilators, inhaled corticosteroids, or systemic corticosteroids 9
Identifying airway malacia helps avoid inappropriate treatment, as beta-agonists may adversely affect airway dynamics in these children, as noted by the American Thoracic Society 9

The British Thoracic Society recommends using MDI with spacer device as an alternative to nebulizer equipment, with salbutamol 100 μg per actuation, repeat up to 20 times, or terbutaline 250 μg per actuation, repeat up to 20 times 5, 6

The American College of Chest Physicians recommends continuing nebulized treatments until clinical improvement is sustained 4
Transition to hand-held inhaler therapy at least 24 hours prior to discharge to ensure stability, as suggested by the British Thoracic Society 8, 4

The American College of Chest Physicians recommends avoiding oxygen as driving gas in patients with documented CO2 retention and acidosis; use compressed air instead 4
The British Thoracic Society recommends avoiding ipratropium in patients with glaucoma risk without using a mouthpiece to prevent eye exposure 10